test your knowledge
How the world got lost on
the road to an anti-aging pill
Subscribe to our newsletter to receive email notifications when new articles are posted.
October 17, 2010: by Bill Sardi
A published report in the Canadian Journal of Physiology and Pharmacology (Volume 88, pages 1017-1025) today confirms that Longevinex® is the first branded resveratrol-based dietary supplement shown to exhibit cardio-protection, that is, it preconditions the heart so if a future heart attack occurs, the patient (in this instance, a laboratory rat) won’t succumb to this unexpected event. An abstract of the report can be viewed online (click here), and the full paper is also available for free public viewing (PDF version / HTML version)
The experiment showed that Longevinex®, a multi-ingredient nutriceutical that provides resveratrol in a matrix with quercetin, rice bran phytate, ferulic acid and vitamin D3, exerts cardio-protective action equivalent to that produced by plain resveratrol at a dose 40% lower than prior published studies (175 mg resveratrol, 100 mg resveratrol/Longevinex matrix).
The amount of scar tissue (fibrosis) produced by the intentionally-induced heart attack was significantly lower in Longevinex®-treated than untreated animals.
Size of heart attack in rodents given no treatment (vehicle)
compared to Longevinex®. White area = scarring (fibrosis).
While consumers and even scientists may now assume subsequent human studies will follow, it would be impossible to reproduce the same experiment in humans as rodent hearts were removed from the chest, their hearts were then perfused (supplied with nutrients) artificially and subjected to a “heart attack” of 30 minutes duration, and then reperfused.
Since it would be unethical to conduct a human study where patients at high risk for a heart attack were given a placebo (inactive pill) and compared with Longevinex®, the only way to proceed now is for modern medicine to begin prescribing such a pill along with other common heart medications and then conduct retrospective analysis in a similar way aspirin was shown to prevent heart attacks.
However, little impetus has been shown by cardiologists to prescribe red wine pills such as Longevinex®. Consumers will need to make their own self-guided decision regarding the application of this animal study to human heart health.
The Advanced Cardiology Institute in Ft. Lee, New Jersey, a non-invasive heart center, is an exception, and has recommended Longevinex® to its patients for over a year now, and may be the only cardiology group in the U.S. that actively prescribes a red wine pill.
Greater importance is given to this study in light of the fact that 50% of people who succumb to a sudden-mortal heart attack were taking aspirin on the day of their demise. Aspirin isn’t working. There is now hope that these needless premature deaths can be averted with a red wine pill.
Upcoming studies will soon reveal an unprecedented dosage/safety profile of Longevinex® and its profound genomic effect upon heart tissue as measured by microRNA analysis.
Bill Sardi, managing partner
Resveratrol Partners LLC, dba Longevinex®
P.S. – Consumers often ask how they will know Longevinex® is working. While many Longevinex® users report profound mental clarity, improved stamina, faster hair growth and improved circulation (Viagra-like effects), if cardio-protection observed in animals can be reproduced in humans, then it would be satisfying to know that consumers might experience no noticeable changes but acquire protection in the event of a future heart attack. It is believed that the red-wine-drinking French experience small heart attacks, but they don’t die from them, which may be why there are so many long-living Frenchmen.